We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Cadence Design Systems
CDNS
$93.5B
| $5.1M | 0.07% |
77,138
+29,533
| +62% | +$2.08M |
|
302
MGM Resorts International
MGM
$11.8B
| $5.08M | 0.07% |
183,315
-2,544
| -1% | -$73.1K |
|
303
CytomX Therapeutics
CTMX
$725M
| $5.08M | 0.07% |
687,833
| – | – |
|
304
Baxter International
BAX
$12B
| $5.06M | 0.07% |
57,887
-16,159
| -22% | -$1.38M |
|
305
Martin Marietta Materials
MLM
$34.2B
| $5.04M | 0.07% |
18,396
+2,702
| +17% | +$668K |
|
306
Vornado Realty Trust
VNO
$7.47B
| $5.02M | 0.07% |
78,902
+50,419
| +177% | +$3.17M |
|
307
Robert Half
RHI
$4.04B
| $4.99M | 0.07% |
89,670
+46,738
| +109% | +$2.64M |
|
308
iShares MSCI Canada ETF
EWC
$6.12B
| $4.99M | 0.07% |
172,625
-44,600
| -21% | -$1.27M |
|
309
NeoGenomics
NEO
$1.73B
| $4.97M | 0.07% |
260,201
+84,000
| +48% | +$1.97M |
|
310
Royal Bank of Canada
RY
$291B
| $4.97M | 0.07% |
61,250
-28,218
| -32% | -$2.2M |
|
311
BorgWarner
BWA
$13B
| $4.97M | 0.07% |
153,956
+84,123
| +120% | +$2.71M |
|
312
Welltower
WELL
$177B
| $4.96M | 0.07% |
54,680
+5,786
| +12% | +$503K |
|
|
EXAS
313
DELISTED
Exact Sciences
EXAS
| $4.94M | 0.07% |
54,642
+20,183
| +59% | +$2.3M |
|
|
CXO
314
DELISTED
CONCHO RESOURCES INC.
CXO
| $4.92M | 0.07% |
72,460
+30,027
| +71% | +$2.44M |
|
315
Campbell Soup
CPB
$6.69B
| $4.92M | 0.07% |
104,788
+85,925
| +456% | +$3.71M |
|
316
CSX Corp
CSX
$95.6B
| $4.87M | 0.06% |
210,936
-4,854
| -2% | -$113K |
|
317
Sysco
SYY
$40.2B
| $4.82M | 0.06% |
60,731
+4,043
| +7% | +$297K |
|
318
General Motors
GM
$77.9B
| $4.77M | 0.06% |
127,198
+6,771
| +6% | +$260K |
|
319
Blackrock
BLK
$164B
| $4.75M | 0.06% |
10,669
+377
| +4% | +$168K |
|
320
J.M. Smucker
SJM
$12.9B
| $4.75M | 0.06% |
43,217
+31,137
| +258% | +$3.47M |
|
321
SS&C Technologies
SSNC
$18.2B
| $4.75M | 0.06% |
92,056
+37,376
| +68% | +$1.91M |
|
322
Rigel Pharmaceuticals
RIGL
$707M
| $4.63M | 0.06% |
+247,800
| New | +$5.12M |
|
323
Capri Holdings
CPRI
$1.81B
| $4.58M | 0.06% |
138,129
+7,190
| +5% | +$230K |
|
324
CF Industries
CF
$18.6B
| $4.55M | 0.06% |
92,544
-19,682
| -18% | -$954K |
|
325
D.R. Horton
DHI
$41.1B
| $4.54M | 0.06% |
86,211
+3,262
| +4% | +$156K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.